FINWIRES · TerminalLIVE
FINWIRES

Research Alert: CFRA Maintains Hold Rating On Shares Of Waters Corporation

By

-- CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:

We raise our 12-month price target to $370 from $335, based on 25.5x our 2026 EPS estimate of $14.50 (up from $14.39; 2027 EPS down $0.05 to $16.34). This is a discount to WAT's three- and five-year historical forward P/E averages of 26.3x and 27.4x, respectively. We see ongoing weakness in academic/government end markets. We also note ongoing policy challenges in China, a key market for several U.S. life sciences tools and services firms, including headwinds for immunodiagnostics from China's diagnosis-related group reimbursement updates. While uncertainty remains regarding WAT's ability to fully realize anticipated synergies from the BDX deal, we view Q1 results as encouraging. The acquired Biosciences and Diagnostic Solutions businesses generated $520M in revenue since closing, $40M above guidance, representing a meaningful sequential improvement from Q4 2025. Of note, the Biosciences division saw just a 1% sales decline on a full-quarter pro forma basis, compared to a 10% decline in Q4 2025.

Related Articles

Mining & Metals

Earnings Flash (KBL.TO) K-Bro Linen Reports Q1 Revenue $139.1M, Up 52.9% YoY

$KBL.TO
Equities

Occidental Petroleum Q1 Adjusted Earnings Rise, Revenue Falls

Occidental Petroleum (OXY) reported Q1 adjusted earnings late Tuesday of $1.06 per diluted share, up from $0.87 a year earlier.Analysts polled by FactSet expected $0.60.Revenue for the three months ended March 31 was $5.23 billion, down from $5.70 billion a year earlier.Analysts surveyed by FactSet expected $5.44 billion.

$OXY
Mining & Metals

Curaleaf Swings to Q1 Profit As Revenues Beat Expectations

Curaleaf (CURA.TO) reported a swing to a surprise first-quarter profit, boosted by better than expected revenues.The company reported net income from continuing operations of US$70.1 million, or US$0.09 per share, compared with a loss of US$50.1 million, or a loss of US$0.09 per share. Analysts polled by FactSet had forecast a loss of US$0.08 per share.Revenue climbed 6% over the same period, to US$324 million, beating the US$317 million forecast."The macro headwinds that constrained growth over the past three years are now beginning to turn into meaningful tailwinds. Moreover, the historic rescheduling of medical cannabis provides a shift in the trajectory of our business and the industry overall, for which we are well-positioned," said chief executive Boris Jordan. "The investments we've made in the core pillars of our "Built for Growth" strategy are translating directly into tangible performance," he added.Curaleaf shares closed up $0.28, to $4.73 on Tuesday on the Toronto Stock Exchange.

$CURA.TO$HMMJ.TO